The relative efficacy and safety of cephradine and cefazolin were compared in 180 patients with a variety of serious infections caused by susceptible organisms. The patients were randomly assigned to one of two groups of 90 patients each. Most patients received 2 to 4 g per day, administered by intravenous injection in four equally divided doses, for a minimum of 4 days. Based on the clinical and microbiological results, the two cephalosporins were found to be comparable in therapeutic effectiveness. Toxicity was not a problem with either drug.
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Cephradine is a broad-spectrum cephalosporin antibiotic that is active against both grampositive and gram-negative pathogens and effective in eradicating most penicillinase-producing organisms known to be resistant to penicillin G, penicillin V, and ampicillin. Clinical trials have shown cephradine to be effective in treating a wide variety of infections caused by susceptible organisms both in adults and in children, and to have a low incidence of adverse reactions (3) (4) (5) (7) (8) (9) (10) .
Cefazolin is a semisynthetic cephalosporin with an antibacterial spectrum similar to that of cephaloridine, cephalothin, and other available cephalosporins. It is bactericidal, interfering with cell wall synthesis in bacteria in a manner similar to that of other cephalosporins and penicillins, and it can be used only parenterally (2) .
Cefazolin has a great affinity for serum protein (74-86% bound) compared to a minimal (6-20%) protein binding of cephradine (6) . The apparent volume of distribution of cephradine is 21 ± 0.1 liters/1.73 m2 of body surface area, whereas that of cefazolin is 11.0 ± 1.2 liters. Cephradine and cefazolin have been used in the treatment of genitourinary, gastrointestinal and respiratory tract infections, and in infections of the skin and soft tissues. Patients were randomly assigned to treatment with either cephradine or cefazolin. The daily dosage of both drugs was the same for a given indication. With a few exceptions, the total daily dosage was 2 to 4 g administered by intravenous injection in four equally divided doses.
A dosage regimen of 500 mg four times a day was considered adequate for patients with uncomplicated pneumonias, urinary tract infections, and skin and soft tissue infections. Septicemia was treated with 750 to 1,000 mg four times a day. The pediatric dosage was 50 mg/kg per day in four equally divided doses.
Organisms isolated from the site of infection (within 48 h before starting therapy) were identified and tested for susceptibility to cephalosporins by the KirbyBauer method (1 
RESULTS
The two treatment groups are compared in Table 2 with respect to age, sex, and diagnosis. The total dose administered intravenously and the duration of treatment are shown in Table 3 The infections treated and the causative organisms were comparable in the two drug groups (Table 4) . From some patients with pneumonia or bronchopneumonia, no pathogen was isolated; and the diagnosis was based on the presence of classical symptoms of pneumonia and positive X-ray findings. Exclusive of these patients with "classical" pneumonia, one or more pathogens were isolated from 83 (92%) patients in the cephradine group and 82 (91%) patients in the cefazolin group. Multiple infections were present in five patients. Two patients in the cephradine group were treated concurrently for a urinary tract infection and pneumonia. Urinary tract infections were present in the three cefazolin-treated patients. Those patients also had concurrent infections: septicemia in two and pneumonia in one. The infecting organism was eradicated in 4 days or less from 63 (76%) patients in the cephradine group as compared with 54 (65%) in the cefazolin group. The infecting organism was never cleared during therapy from three (4%) patients treated with cephradine and from two (2%) treated with cefazolin.
The assessment of overall responses to the drugs is correlated with the diseases under treatment in Table 5 . The percentages of satisfactory (excellent and good) responses achieved with each drug in the treatment of urinary tract infection and pneumonia are compared in Fig. 1 . The satisfactory responses ranged from 87 to bCFZ, Cefazolin.
-, Not isolated. after intravenous administration. However, its apparent volume of distribution is less than that of cephradine, and the high order of protein binding could limit its concentration in the infected tissues. With regard to clinical response and time required for eradication of the causative organism, there were no statistically significant differences between the two cephalosporins. Notwithstanding pharmacokinetic differences, the results of this study indicate that cephradine and cefazolin are comparable in therapeutic effectiveness. Toxicity was not a problem with either drug.
